ALS Liga
  • NL
  • FR
  • EN
  • DE
Partnership
Register
DONATION
  • About ALS
    • What is ALS?
    • Diagnosis
    • Variants
    • Heredity
  • Dealing with ALS
    • Living with ALS
    • Care
      • Home care
      • Revalidation
      • Nutrition
    • Support
      • Casemanager
      • ALS Liaison
      • Emergency procedure PVB
      • Allowances
      • ALS Mobility & Digitalk
    • Tips
    • Testimonials
    • Leaflets & Brochures
  • About us
    • Mission & Vision
    • Who are we?
    • What do we do?
      • Objectives
      • Lobby & Relations
      • Media
        • Campaigns
        • Press articles
        • ALS TV
        • Photo album
        • Newsletters
    • ALS Fora
    • Annual Report
    • Contact
      • ALS Liga
      • Collaborations
  • Education
    • E-Learning
    • Info sessions
    • Formation
    • Training day
  • Contribute
    • Donations
    • Will
    • Enterprises
    • Funds
    • Volunteers of all kind
    • ALS Shop
    • Action platform’
Research
What is ALS
Trials
A Cure for ALS
Vorig artikel
Volgend artikel
How new gene therapies are transforming genetic testing for ALS
16/11/2026

17 July 2026

In Canada, approval of targeted treatment has driven broad surge

  • The approval of a gene-targeted therapy for ALS has revolutionized genetic testing in Canada, a study found.
  • All ALS patients, including those with no family history, are now routinely offered genetic testing.
  • This shift helps identify patients who may be eligible for specific treatments, such as the approved therapy Qalsody.

The anticipated availability and subsequent approval in Canada of the first gene-targeted therapy for certain people with amyotrophic lateral sclerosis (ALS) has transformed how doctors in the North American nation approach genetic testing for the rare neurodegenerative disease, according to a new study.

Over the last five years, Canadian ALS clinics have shifted from offering genetic testing mainly to people with a family history of ALS to routinely testing all patients, regardless of whether the disease appears to run in their family, the researchers found. Indeed, the data show 100% of physicians treating people with sporadic ALS — meaning their disease occurred spontaneously — now offer such testing.

The researchers say the change was influenced by the availability of Qalsody (tofersen), a medication conditionally approved in Canada in 2025, and the growing importance of identifying people eligible for treatment.

“Genetic testing practices in Canada shifted substantially during late-stage clinical development and following regulatory approval of a gene-targeted therapy,” namely Qalsody, the researchers wrote, adding that the new study findings illustrate how “therapeutic breakthroughs can redefine national clinical standards.”

The study, “A changed landscape: five-year retrospective on the paradigm shift in genetic testing practices for ALS in Canada,” was published in the European Journal of Human Genetics.

For many years, genetic testing in ALS was generally reserved for people with familial ALS, who have a known family history of the disease. People with sporadic ALS, who make up about 90% of cases and have no known affected relatives, were tested much less often because of the assumption this form of the disease lacked a genetic cause.

Guidelines now urge ALS genetic testing regardless of family history

However, research in recent years has shown that about 10% to 20% of sporadic ALS cases also have an identifiable genetic cause.

Reflecting this evidence, recent guidelines recommend offering genetic testing to everyone diagnosed with ALS, regardless of family history. The emergence of therapies targeting specific ALS mutations, as well as the need to determine eligibility for treatment, has further emphasized the importance of universal genetic testing, supporters say.

One example is Qalsody, conditionally approved in the U.S. in 2023 and in Canada two years later for people with ALS associated with mutations in the SOD1 gene. The RNA-based therapy is designed to lower levels of SOD1, the toxic protein that drives the disease in these patients.

Qalsody’s conditional approval was based on preliminary evidence from clinical trials showing that treatment reduced levels of neurofilament light chain (NfL), a marker of nerve damage, which regulators considered a good surrogate marker to predict its ability to slow disease progression. Confirmatory data will be needed for the treatment to advance to full approval.

Increase in testing in Canada linked directly to Qalsody approval

To evaluate how genetic testing practices have shifted in response to therapeutic developments, a team of researchers surveyed members of the Canadian ALS Research Network at three time points: in 2020, 2022, and 2025. CALS is a nationwide network currently consisting of 55 neurologists and physiatrists working across 24 specialized ALS clinics in Canada.

During the first two surveys, each clinic submitted a single response, while in 2025, multiple physicians from the same clinic were encouraged to participate to identify diverging practices within clinics.

In this final survey, researchers received responses from 33 physicians representing 21 of Canada’s 24 specialized ALS clinics. A total of 11 clinics took part in all three surveys, allowing the team to compare changes in practice over five years.

The surveys showed a dramatic increase in genetic testing for sporadic ALS. In 2020, one-third of physicians routinely offered genetic testing to these patients. That number rose to more than half (57%) in 2022 and reached 100% in 2025, meaning every responding physician reported routinely offering genetic testing regardless of family history.

Genetic testing for familial ALS was already common in 2020, with 93% of physicians routinely offering it, and reached 100% by 2025, the data showed.

Most physicians (78%) said their genetic testing practices had changed between 2020 and 2022, mainly due to broader access to comprehensive genetic testing and increased testing of people with sporadic ALS. By 2025, 61% reported that Qalsody’s approval had directly influenced how they approach genetic testing.

This study demonstrates a transformative paradigm shift in practice, marked by a surge in genetic testing for individuals with no family history of ALS.

Changes extended beyond people with ALS. The proportion of physicians offering predictive genetic testing to healthy at-risk relatives increased from 37% in 2020 to 61% in 2025. The share who routinely monitored healthy people known to carry ALS-causing genetic mutations before symptoms also rose, from 30% to 44%, the data showed.

However, monitoring practices varied considerably among clinics, and several physicians said they routinely followed only people carrying SOD1 mutations because of the availability of Qalsody.

“This study demonstrates a transformative paradigm shift in practice, marked by a surge in genetic testing for individuals with sporadic ALS,” the researchers concluded. “It highlights that, with the availability of a genetically targeted treatment and clear clinical utility, rapid adaptation in clinical practice is possible.”

Source: ALS News Today

Vorig artikel
Volgend artikel

ALS Liga België vzw / Ligue SLA Belgique asbl

  • Press
  • Webshop
  • Useful links
  • Sitemap
  • Conditions of use
  • Privacy policy
  • Facebook
  • Instagram
  • YouTube
  • X
  • LinkedIn

Copyright © 2024 ·

ALS Liga

· All rights reserved



Beheer toestemming
Om de beste ervaringen te bieden, gebruiken wij technologieën zoals cookies om informatie over je apparaat op te slaan en/of te raadplegen. Door in te stemmen met deze technologieën kunnen wij gegevens zoals surfgedrag of unieke ID's op deze website verwerken. Als je geen toestemming geeft of uw toestemming intrekt, kan dit een nadelige invloed hebben op bepaalde functies en mogelijkheden.
Functioneel Always active
De technische opslag of toegang is strikt noodzakelijk voor het legitieme doel het gebruik mogelijk te maken van een specifieke dienst waarom de abonnee of gebruiker uitdrukkelijk heeft gevraagd, of met als enig doel de uitvoering van de transmissie van een communicatie over een elektronisch communicatienetwerk.
Voorkeuren
De technische opslag of toegang is noodzakelijk voor het legitieme doel voorkeuren op te slaan die niet door de abonnee of gebruiker zijn aangevraagd.
Statistieken
De technische opslag of toegang die uitsluitend voor statistische doeleinden wordt gebruikt. De technische opslag of toegang die uitsluitend wordt gebruikt voor anonieme statistische doeleinden. Zonder dagvaarding, vrijwillige naleving door uw Internet Service Provider, of aanvullende gegevens van een derde partij, kan informatie die alleen voor dit doel wordt opgeslagen of opgehaald gewoonlijk niet worden gebruikt om je te identificeren.
Marketing
De technische opslag of toegang is nodig om gebruikersprofielen op te stellen voor het verzenden van reclame, of om de gebruiker op een website of over verschillende websites te volgen voor soortgelijke marketingdoeleinden.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
Bekijk voorkeuren
  • {title}
  • {title}
  • {title}